Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure

NCT07669623 · tracked via the Priya Life Science China tracker
Sponsor
Cui Hong Zheng
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-26

Condition(s) studied

Implantation Failure

Investigational drug(s) / intervention(s)

Placebo Groupacupuncture group 1acupuncture group 2

Placebo Group: nonpenetrating placebo needles

acupuncture group 1: indwelling intradermal needles

acupuncture group 2: combining fire needle and regular acupuncture

Study summary

To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure

Eligibility

Sex
FEMALE
Min age
—
Max age
39 Years
Healthy volunteers
No
Inclusion Criteria: 1. Meets the criteria for RIF diagnosis (≥ 3 instances of unsuccessful transfer of high-quality embryos). 2. Age: \< 40 years. 3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET). 4. Possession of a transplantable frozen blastocyst (≥3BB). 5. Endometrial thickness \>7 mm within the period of endometrial transformation. Exclusion Criteria: 1. Individuals planning to undergo preimplantation genetic diagnosis (PGD). 2. Recipients of egg donations. 3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms). 4. Patients with known embryo-related factors leading to implantation failure. 5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on). 6. Those with significant abnormalities in immunity or coagulation. 7. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months. 8. Individuals with untreated hydrosalpinx; 9. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/ m2. 10. Men with severe abnormalities in semen quality. 11. Individuals with a history of needle phobia. 12. Individuals who have previously participated in this study or received acupuncture treatment within the past three months; 13. Any other conditions deemed unsuitable for participation by the researchers.

Primary outcome measure(s)

  • clinical pregnancy — 2 years
    defined as ultrasonographic detection of an intrauterine gestational sac following embryo transfer

Trial sites (1)

FacilityCityRegionStatus
Tongji Hospital,Tongji medical college,HUST Wuhan Hubei
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07669623 on ClinicalTrials.gov ↗ ← All trials in China